IDO1 (indolamine 2,3-dioxygenase)
An enzyme that converts the amino acid tryptophan into kynurenine; over-activation of IDO1 in Alzheimer's disease disrupts astrocyte glycolysis and lactate production, leading to neuronal energy failure
As defined in Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
Where it comes up · 1
Most important claims · 8 of 8Search all claims for “IDO1 (indolamine 2,3-dioxygenase)” →
- The effects of IDO1 inhibition on metabolic rescue are replicatable in human cells, though actual experiments in live humans with Alzheimer's disease have not yet been conducted.Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
- IDO1 (indolamine 2,3-dioxygenase) is an enzyme that converts the amino acid tryptophan into a molecule called kynurenine (kyn).Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
- The classical amyloid and tau pathologies in Alzheimer's disease each converge on and increase the activity of the IDO1 enzyme, which increases kynurenine levels and thereby inhibits astrocyte glycolysis, decreasing lactate transfer to neurons and starving neurons of energy.Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
- Human astrocytes from patients with late-onset Alzheimer's disease have lower tryptophan levels and higher kynurenine levels, demonstrating that the IDO1-kynurenine pathway is active in the human Alzheimer's brain.Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
- The IDO1-kynurenine pathway was found to be relevant in three independent animal models of Alzheimer's disease and has parallels in human brains and human brain cells.Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
- Inhibiting IDO1 restores astrocyte glycolysis and lactate production, improves metabolic function in the brain, improves neuronal function and markers of neuronal learning like long-term potentiation, and improves memory in animal models.Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
- The IDO1-kynurenine pathway is also involved in other forms of neurodegenerative diseases like Parkinson's disease, leading to the possibility that targeting this pathway could have positive effects on dementia and neurodegenerative diseases beyond just Alzheimer's disease.Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage
- There exists a cancer drug named PF-06840003 that targets IDO1, raising the possibility of repurposing this cancer metabolism therapy for Alzheimer's disease treatment in live humans.Metabolizing Alzheimer’s: A New Key to Stopping Brain Damage